Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Seal

Showing results (21-30 of 58) with videos related to

Pageof 6
Sort By:
Advances in Therapy|July 16, 2014
Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patientsZhiyuan Zheng, Eberechukwu Onukwugha, Nader Hanna, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 5, 2021
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare PerspectiveRanee Mehra, Candice Yong, Brian Seal, et al.
Head & Neck|March 10, 2020
Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapyRanee Mehra, Huan Huang, Brian Seal, et al.
Journal of Geriatric Oncology|April 15, 2014
Skeletal-related events and mortality among older men with advanced prostate cancerEberechukwu Onukwugha, Candice Yong, C Daniel Mullins, et al.
Pharmacoeconomics|May 6, 2017
Evaluation of Healthcare Interventions and Big Data: Review of Associated Data IssuesCarl V Asche, Brian Seal, Kristijan H Kahler, et al.
Cancer Reports (Hoboken, N.J.)|September 8, 2021
Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims studyLincy S Lal, Abdalla Aly, Lisa B Le, et al.
Cancer Medicine|January 10, 2014
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patientsZhiyuan Zheng, Nader Hanna, Eberechukwu Onukwugha, et al.
The Oncologist|April 30, 2016
Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon CancerKaloyan A Bikov, C Daniel Mullins, Anna Hung, et al.
Urologic Oncology|January 3, 2017
Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancerEberechukwu Onukwugha, Candice Yong, Michael Naslund, et al.
Hepatic Oncology|August 14, 2023
Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology settingAbdalla Aly, Nicole Fulcher, Brian Seal, et al.
Pageof 6

Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
Advances in Therapy|July 16, 2014
Cost-effectiveness of second-line chemotherapy/biologics among elderly metastatic colon cancer patientsZhiyuan Zheng, Eberechukwu Onukwugha, Nader Hanna, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 5, 2021
Cost-Effectiveness of Durvalumab After Chemoradiotherapy in Unresectable Stage III NSCLC: A US Healthcare PerspectiveRanee Mehra, Candice Yong, Brian Seal, et al.
Head & Neck|March 10, 2020
Real-world treatment patterns for patients with metastatic head and neck squamous cell carcinoma treated with immuno-oncology therapyRanee Mehra, Huan Huang, Brian Seal, et al.
Journal of Geriatric Oncology|April 15, 2014
Skeletal-related events and mortality among older men with advanced prostate cancerEberechukwu Onukwugha, Candice Yong, C Daniel Mullins, et al.
Pharmacoeconomics|May 6, 2017
Evaluation of Healthcare Interventions and Big Data: Review of Associated Data IssuesCarl V Asche, Brian Seal, Kristijan H Kahler, et al.
Cancer Reports (Hoboken, N.J.)|September 8, 2021
Healthcare costs related to adverse events in hepatocellular carcinoma treatment: A retrospective observational claims studyLincy S Lal, Abdalla Aly, Lisa B Le, et al.
Cancer Medicine|January 10, 2014
Does the type of first-line regimens influence the receipt of second-line chemotherapy treatment? An analysis of 3211 metastatic colon cancer patientsZhiyuan Zheng, Nader Hanna, Eberechukwu Onukwugha, et al.
The Oncologist|April 30, 2016
Patterns of Biologics Use Across Treatment Lines in Elderly (Age >65) Medicare Patients With Metastatic Colon CancerKaloyan A Bikov, C Daniel Mullins, Anna Hung, et al.
Urologic Oncology|January 3, 2017
Specialist visits and initiation of cancer-directed treatment among a large cohort of men diagnosed with prostate cancerEberechukwu Onukwugha, Candice Yong, Michael Naslund, et al.
Hepatic Oncology|August 14, 2023
Clinical outcomes by Child-Pugh Class in patients with advanced hepatocellular carcinoma in a community oncology settingAbdalla Aly, Nicole Fulcher, Brian Seal, et al.
Pageof 6